Back to Results
First PageMeta Content
Vrije Universiteit Brussel / Immune system / Immunotherapy / Merck & Co. / Single-domain antibody / Serono / Pharmaceutical industry / Cancer immunotherapy / Medicine / Immunology / Ablynx


ABLYNX ANNOUNCES WORLDWIDE CANCER IMMUNOTHERAPY DISCOVERY COLLABORATION AND LICENSING AGREEMENT WITH MERCK Utilising the Nanobody® technology to generate multi-specific drugs GHENT, Belgium, February 3, 2014 –Ablynx [
Add to Reading List

Document Date: 2014-02-02 12:55:18

Open Document

File Size: 377,00 KB

Share Result on Facebook

City

GHENT / Brussels / /

Company

Merck & Co. / Eddingpharm / Novartis / AbbVie / Ablynx / Merck Research Laboratories / Boehringer Ingelheim / Merck Serono / /

Country

Belgium / United States / Canada / /

Currency

EUR / /

/

Event

Business Partnership / /

IndustryTerm

media relations / biopharmaceutical / treatment of a wide range of cancer / manufacturing / pharmaceutical / /

MedicalCondition

cancer / serious human diseases / pulmonary disease / inflammation / tumours / /

MedicalTreatment

immunotherapies / /

Person

Edwin Moses / Roger M. Perlmutter / Lindsey Neville / /

/

Position

CEO / President / Director Investor Relations / /

Product

Nanobody platform / Nanobody / /

Technology

neuroscience / immunotherapeutics / Nanobody technology / /

URL

www.ablynx.com / /

SocialTag